TANZANIA INACTIVATED POLIO VACCINE (IPV) SUPPORT
This Decision Letter sets out the Programme Terms of a Programme.

1. **Country:** Tanzania

2. **Grant Number:** 1518-TZA-25b-X / 1518-TZA-25c-X / 15-TZA-08h-Y

3. **Date of Decision Letter:** 6 March 2015 (This decision letter replaces the previous one dated 1 July 2014 to reflect the change in product presentation.)

4. **Date of the Partnership Framework Agreement:** 01 July 2013

5. **Programme Title:** NVS, IPV Routine

6. **Vaccine type:** Inactivated Polio Vaccine (IPV)

7. **Requested product presentation and formulation of vaccine**¹: Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. **Programme Duration**²: 2015 - 2018

9. **Programme Budget** (indicative) (subject to the terms of the Partnership Framework Agreement):

   Please note that endorsed or approved amount for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>Total ³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Budget (US$)</td>
<td>US$3,236,981</td>
<td>US$4,826,500</td>
<td>US$3,905,500</td>
<td>US$11,968,981</td>
</tr>
</tbody>
</table>

10. **Vaccine Introduction Grant:** US$1,599,000 already disbursed to Tanzania on 25 July 2014 as per Decision Letter dated 1 July 2014.

11. **Indicative Annual Amounts** (subject to the terms of the Partnership Framework Agreement):⁴ The Annual Amounts for 2015 and 2016 have been amended

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2015</th>
<th>2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>1,526,800</td>
<td>2,389,500</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>2,896,400</td>
<td>844,800</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>31,875</td>
<td>9,300</td>
</tr>
</tbody>
</table>

   **Annual Amounts (US$)**
   - US$3,236,981
   - US$4,826,500

12. **Procurement agency:** UNICEF

13. **Self-procurement:** Not applicable

14. **Co-financing obligations:**
   Gavi’s usual co-financing requirements do not apply to IPV. However, Tanzania is encouraged to contribute to vaccine and/or supply costs for IPV.

---

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the programme.

³ This is the total amount endorsed by Gavi for 2015 to 2017.

⁴ This is the amount that Gavi has approved.
15. **Operational support for campaigns:** Not applicable

16. The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts:

<table>
<thead>
<tr>
<th>Reports, documents and other deliverables</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Progress Report or equivalent</td>
<td>To be agreed with Gavi Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial Clarifications:** Not applicable

18. **Other conditions:**

If Tanzania envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Tanzania.

REMINDER: As a Partnership Framework Agreement requirement: "...the government shall maintain, where available at a reasonable cost, all risk property insurance on the Programme assets (including vaccines and vaccine related supplies) and comprehensive general liability insurance with financially sound and reputable insurance companies". In this context, kindly provide Gavi with a copy of such insurance policy to ensure compliance with this requirement.

---

**On behalf of Gavi**

Hind Khatib-Othman  
Managing Director, Country Programmes  
6 March 2015